MBX Biosciences, Inc. Common Stock (MBX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 55.87 |
| Open | 55.97 |
| Day High | 57.42 |
| Day Low | 54.21 |
| 52-Week High | 72.64 |
| 52-Week Low | 20.21 |
| Volume | 326,392 |
| Average Volume | 512,379 |
| Market Cap | 2.62B |
| PE | -22.57 |
| EPS | -2.41 |
| Moving Average 50 Days | 57.82 |
| Moving Average 200 Days | 45.58 |
| Change | -1.47 |
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
GlobeNewswire Inc.
Mar 10, 2026 12:00 PM GMT
CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of e
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
GlobeNewswire Inc.
Mar 09, 2026 2:21 PM GMT
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows. CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Bio
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, developm